Drug reference
bishydroxycoumarin
Coumarin derivative, Vitamin K antagonist · Anticoagulant
Coumarin derivative, Vitamin K antagonistAnticoagulant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Interferes with the synthesis of vitamin K dependent clotting factors in the liver by inhibiting vitamin K epoxide reductase.
Indications
Anticoagulation (not preferred now)
Dosing
- Adult
- Loading: 200 mg for 2 days; Maintenance: 50–100 mg
Pharmacokinetics
Onset
Delayed (1-3 days)
Half-life
25–100 hours (dose dependent)
Side effects
Common
Frequent g.i.t. disturbances
Related guidelines
GI bleeding on antiplatelet or anticoagulant therapy
CSI · Cardiology · 2020
Venous thromboembolism prophylaxis
ASH · Haematology · 2018
Anticoagulant management for dental procedures
ADA_DENTAL · Dentistry · 2015
Sickle cell disease
ASH · Haematology · 2020
Trauma in elderly and frail patients
WSES · Surgery · 2023
Other Coumarin derivative, Vitamin K antagonist drugs
Ask House about bishydroxycoumarin
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e·Updated: 2026-05-10